Viking Therapeutics, Inc. (NASDAQ:VKTX)
Insiders filed in the last 90 days, but none of those trades qualified for scoring — round-trip buys and filings whose price is far off the market are excluded.
No revenue reported, so there is no margin to score.
- Revenue
- $0
- Net income
- -$534.8M
- Net margin
- —
Little or no net debt.
- Total debt
- $4.1M
- Cash
- $125.8M
- Debt / equity
- 0.01
Comfortably covers what is due within a year.
- Current assets
- $517.6M
- Current liabilities
- $109.7M
- Current ratio
- 4.72
Consumes cash and must keep raising it.
- Operating cash flow
- -$418.4M
- Free cash flow
- -$418.4M
Burning cash with under a year of runway — expect a raise.
- Shares outstanding
- 115.9M
- Share growth (1y)
- 3.4%
- Cash runway
- 4 months
Five pillars — profitability, leverage, liquidity, cash generation, dilution & runway — each scored 0–20 from the company’s own income statement, balance sheet and cash-flow statement, then scaled to 100. A pillar the statements cannot answer is left out rather than guessed; fewer than three and no score is shown.
VKTX Income Statement
| Fiscal Period | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|---|
| Period Ending | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 |
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Revenue Growth (YoY) | — | — | — | — | — | — |
| Cost of Revenue | 0.00 | 0.00 | 94.00 K | 114.00 K | 0.00 | 0.00 |
| Gross Profit | 0.00 | 0.00 | -94.00 K | -114.00 K | 0.00 | 0.00 |
| SG&A Expense | 16.84 M | 13.97 M | 11.28 M | 8.61 M | 14.42 M | 14.08 M |
| R&D Expense | 115.75 M | 150.15 M | 153.46 M | 89.95 M | 60.15 M | 41.39 M |
| Operating Expenses | 132.60 M | 164.13 M | 164.74 M | 98.56 M | 74.57 M | 55.47 M |
| Operating Income | -132.60 M | -164.13 M | -164.74 M | -98.56 M | -74.57 M | -55.47 M |
| Pretax Income | -128.02 M | -158.32 M | -157.66 M | -90.79 M | -65.56 M | -45.63 M |
| Tax Provision | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Income | -128.02 M | -158.32 M | -157.66 M | -90.79 M | -65.56 M | -45.63 M |
| EPS (Basic) | -1.10 | -1.37 | -1.38 | -0.81 | -0.58 | -0.41 |
| EPS (Diluted) | -1.10 | -1.37 | -1.38 | -0.81 | -0.58 | -0.41 |
| Shares Outstanding | 115.92 M | 115.57 M | 114.00 M | 112.32 M | 112.13 M | 112.07 M |
Quarterly figures; YoY compares the same fiscal quarter a year earlier. Source: public market data.